MannKind Corporation June 15th Short Interest Update

MannKind Corporation (NASDAQ:MNKD) stated loss of 5,080,236 shares or 5.9% in the short interest. The short interest registered from 86,478,598 on May 31,2016 to 81,398,362 on June 15,2016. In terms of floated shares, the shorted positions stood at 25.2%. The stock has been averaging 4,326,371 shares daily in trading and would need 19 days to cover the shorts. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

MannKind Corporation (NASDAQ:MNKD): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.10 and $1.10 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $1.30. The buying momentum continued till the end and the stock did not give up its gains. It closed at $1.25, notching a gain of 0.81% for the day. The total traded volume was 14,839,659 . The stock had closed at $1.24 on the previous day.

The company shares have dropped -77.84% from its 1 Year high price. On Jul 16, 2015, the shares registered one year high at $5.80 and the one year low was seen on Jan 6, 2016. The 50-Day Moving Average price is $1.02 and the 200 Day Moving Average price is recorded at $1.23.

MannKind Corporation (NASDAQ:MNKD) has climbed 23.76% in the past week and advanced 28.73% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 25.82% and the outperformance has advanced to 32.63% for the last 4 weeks period.

MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Companys product candidate is AFREZZA, inhaled insulin used to control high blood sugar in adults with type one and type two diabetes and also to improve glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a small and portable inhaler. AFREZZA utilizes its Technosphere formulation technology. The Companys Technosphere powders are -based on the Companys fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. The Company manufactures AFREZZA in its Danbury, Connecticut facility.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.